 NEW YORK, Jan. 03, 2023 GLOBE NEWSWIRE -- Y-mAbs Therapeutics, Inc. the Company or Y-mAbs Nasdaq: YMAB a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that its founder, President and Interim Chief Executive Officer, Thomas Gad, will provide an overview and update on the Companys business at the virtual 41st Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, January 11, 2023, at 5:15 PM Eastern Standard Time. The presentation can be accessed via a live audio webcast. 